

EUSTM-2021

SOLID TUMORS THERAPEUTICS

(VIRTUAL CONGRESS)



20 - 26 September 2021

8TH ANNUAL CONGRESS

OF THE EUROPEAN SOCIETY FOR
TRANSLATIONAL MEDICINE ON SOLID TUMORS
THERAPEUTICS (EUSTM-2021)

AGENDA



Co-organizers



Supported by



EUSTM-2021 on Solid Tumors Therapeutics

<https://eutranslationalmedicine.org/eustm-2021/>

<https://eustm-2021.heysummit.com/>

The conference will represent a unique multidisciplinary virtual platform to discuss latest findings, advancements and approaches for effective management of solid tumors.



Talks **50+**



Expected Delegates
3000+



Different countries
40 Plus



ATTENDEES SPECIALTIES



Medical
Oncologists



Oncology
Radiologists



Pathologists



Surgeons



Clinical
Investigators



Health Care
Professionals
(HCPs) involved
in Oncology care.

ATTENDEES BY REGION



- Western Europe: 45%
- Eastern Europe: 25%
- North America: 20%
- Other Regions: 10%

14

CONGRESS THEMES & TRACKS

EUSTM-2021 on Solid Tumors Therapeutics

<https://eutranslationalmedicine.org/eustm-2021/>

<https://eustm-2021.heysummit.com/>

Day 1: 20 September 2021

10:00 (CET)

Overcoming Tumor Antigen Heterogeneity in the Context of CAR T Cell therapy for Solid Tumors

ASTERO KLAMPATSA

Thoracic Oncology Immunotherapy Group, The Institute of Cancer Research, Division of Cancer Therapeutics, London, UK

13:00 (CET)

Modeling Therapy-Induced Tumor Cell State Plasticity to Identify Vulnerabilities for Reducing Disease Burden

JONATHAN A. KELBER

Department of Biology, California State University Northridge (CSUN), Los Angeles, California

15:00 (CET)

Cracking open the undruggable RAS: A Clinical Perspective

DAVID S. HONG

Associate Vice President of Clinical Research, University of Texas M.D. Anderson Cancer Center, Deputy Chair of the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, Houston, USA.

17:00 (CET)

Development of a novel biodegradable chemo-radioembolic formulation for transarterial treatment of hepatocellular carcinoma (Poster Talk)

ASSEEL ALREGIB

School of Medicine, Taylor's University, Subang Jaya, Malaysia

11:00 (CET)

Tumor Endothelial Cells in NSCLC: headmasters of tumor immunity

ANDREAS PIRCHER

Department of Internal Medicine V (Hematology and Oncology) Medizinische Universität Innsbruck, Innsbruck, Austria

14:00 (CET)

Glucocorticoids and Angiogenesis

JULIE GOODWIN

Yale School of Medicine, New Haven, CT, USA

16:00 (CET)

Identification of distinct immune signatures in malignant pleural mesothelioma

CARA HAYMAKER

Director, Oncology Research and Immuno-monitoring Core (ORION) Director, Translational Molecular Pathology and Immunoprofiling Lab, UT MD Anderson Cancer Center, Houston, TX, US



Day 2: 21 September 2021

10:00 (CET)

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs

ARMANDO BARTOLAZZI

Department of Pathology, Sant'Andrea University Hospital, Rome, Italy

13:00 (CET)

Unleashing the potential of liquid biopsy in solid tumors: diagnosis, recurrence and resistance

MARZIA DEL RE

Unit of Clinical Pharmacology and Pharmacogenetics, Dipartimento di Medicina Clinica e Sperimentale, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy

15:00 (CET)

Age of combination therapy in the treatment of advanced RCC: can we do it better?

CHE-KAI TSAO

Medical Director, Ruttenberg Treatment Center, Tisch Cancer Institute, Mount Sinai Hospital, NY, USA

17:00 (CET)

Identifying emerging novel metastatic castration-resistant prostate cancer therapies; understanding PARPi in combination with AR-targeted treatments | satellite symposium

PEDRO BARATA, JORGE A. GARCIA AND ELISABETH HEATH

*Tulane Medical School Department of Internal Medicine, New Orleans, Louisiana, USA.,

*Oncology University Hospitals Seidman Cancer Center, Cleveland, OH, USA. and

*Karmanos Cancer Institute, Wayne State School of Medicine, Detroit, Michigan

11:00 (CET)

Role of calcineurin in affecting tumor growth and the formation of the tumor microenvironment

FRANCESCA GRANUCCI

Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, Italy

14:00 (CET)

Combination of integrated genomics with ex vivo microcancer drug screens to individualize brain cancer therapy

PANOS Z. ANASTASIADIS

Cell Biology Program Director, Cell Adhesion and Metastasis Laboratory Mayo Clinic Cancer Center, Jacksonville, FL, USA

16:00 (CET)

Proteomic and N-glycome profiling of secretome from BRAFV600E mutant colon cancer cells with acquired resistance to vemurafenib (Poster Talk)

IRIS CAR

University of Rijeka, Department of Biotechnology, Rijeka, Croatia



21 SEPTEMBER 2021, 5:00 PM CEST

Identifying emerging novel metastatic castration-resistant prostate cancer therapies; understanding PARPi in combination with AR-targeted treatments.

Learning objectives:

After completing the independent medical educational activity, learners will be able to:

- A. Explain mechanisms of action and risks associated with PARPi alone, as well as in combination with AR inhibitors currently used in practice.
- B. Identify and list gene mutations that are predictive biomarkers to identify PARPi + AR inhibitors- responding mCRPC patients.
- C. Explain the rationale flow in deciphering when it is finally appropriate to have a mCRPC patient put on a PARPi + AR inhibitor combination treatment.
- D. Describe the current landscape of clinical trials that involve the combination of PARPi + AR inhibitor to treat mCRPC.

Certificate of attendance:

The certificates will be given to those attendees who will complete pre & post symposium evaluation quiz.

Conflict of interests:

No known conflict of interests

Acknowledgment:

This symposium is supported by a research grant from Astellas pharma.

Identifying emerging novel metastatic castration-resistant prostate cancer therapies; understanding PARPi in combination with AR-targeted treatments.

21 SEPTEMBER 2021, 5:00 PM CEST

Expert Talk 1: Patient Selection For PARP Inhibitor: Genomic Considerations

PEDRO BARATA

*Tulane Medical School Department of Internal Medicine, New Orleans, Louisiana, USA.

Expert Talk 2: Importance of Genomics in Prostate Cancer: Role of PARPi in CRPC

JORGE A. GARCIA

*Oncology University Hospitals Seidman Cancer Center, Cleveland, OH, USA.

Expert Talk 3: Prostate Cancer PARP Combination Clinical Trials

ELISABETH HEATH

*Karmanos Cancer Institute, Wayne State School of Medicine, Detroit, Michigan.

Expert Panel Discussion and Questions & Answers

PANELISTS: PEDRO BARATA, JORGE A. GARCIA AND ELISABETH HEATH

*Tulane Medical School Department of Internal Medicine, New Orleans, Louisiana, USA., *Oncology University Hospitals Seidman Cancer Center, Cleveland, OH, USA. & *Karmanos Cancer Institute, Wayne State School of Medicine, Detroit, Michigan.



Day 3: 22 September 2021

10:00 (CET)

Investigating protein- and gene-expression of 27 cytokines/chemokines in melanoma patients. Identification of a 4-genes signature

ANTONIO FACCHIANO

Istituto Dermopatico dell'Immacolata (IDI-IRCCS),
Rome, Italy

13:00 (CET)

Molecular Testing and Liquid Biopsy for Ovarian Cancer

JIANYU RAO

UCLA Medical Center, Santa Monica, LA, USA

15:00 (CET)

Ion channel drugs as electroceuticals for reprogramming cancer: exploiting bioelectric controls of cell and tissue function

MICHAEL LEVIN

Tufts University, Medford, USA

11:00 (CET)

MET as a druggable target in solid tumors

QIAN XIE

Department of BioMedical Sciences, Quillen College of Medicine, East Tennessee State University, Johnson City, US

14:00 (CET)

Flexible samarium-153 radiotherapeutic bandage for radiation therapy of skin cancer

WONG YIN HOW

School of Medicine, Faculty of Health & Medical Sciences, Taylor's University, Subang Jaya, Malaysia

16:00 (CET)

Identification of Novel Biomarkers of Response to Irinotecan in Patients with Colorectal Cancer (Poster Talk)

JING LI

Universitat Autònoma de Barcelona, Barcelona, Spain



Day 4: 23 September 2021

10:00 (CET)

Potential prostate cancer targeting strategies revealed by integrative proteogenomics

LEENA LATONEN

School of Medicine, Institute of Biomedicine,
University of Eastern Finland Kuopio, Finland

13:00 (CET)

Mesenchymal stem/stromal cells and the tumor tissue microenvironment

YUFANG SHI

Soochow University Institutes for Translational
Medicine & Shanghai Institute of Nutrition and Health,
Chinese Academy of Sciences, Shanghai, China

15:00 (CET)

Targeting glycosaminoglycans in solid tumors

MADS DAUGAARD

Molecular Pathology & Cell Imaging Core Facility,
Vancouver Prostate Centre Department of Urologic
Sciences, University of British Columbia, Vancouver,
Canada

17:00 (CET)

Role of maintenance immunotherapy in metastatic urothelial carcinoma; which patients are eligible? | satellite symposium

SHILPA GUPTA, VADIM KOSHKIN AND JORGE A. GARCIA

Case Comprehensive Cancer Center, Case Western Reserve University,
Cleveland, Ohio, *Division of Hematology and Oncology, University of California
San Francisco and *Oncology University Hospitals Seidman Cancer Center,
Cleveland, OH, USA

11:00 (CET)

Two retrospective studies on gender differences: chemotherapy toxicities in patients affected by colorectal and pancreatic cancers

SILVIA DE FRANCIA

Department of Clinical and Biological Sciences,
University of Turin, Orbassano (TO), Italy

14:00 (CET)

Vitiligo and vitiligo-associated markers as indicators of response to immunological checkpoint inhibitors in cutaneous melanoma

CRISTINA M. FAILLA

Experimental Immunology Laboratory, IDI-IRCCS, Rome, Italy

16:00 (CET)

Designing a Multi-Epitope Vaccine Against Cancer-Testis Antigens in Non-Small Cell Lung Cancer: an In Silico Approach (Poster Talk)

LEANA RICH M. HERRERA

Polytechnic University of the Philippines, Philippines



23 SEPTEMBER 2021, 5:00 PM CEST

Role of maintenance immunotherapy in metastatic urothelial carcinoma; which patients are eligible?

Learning Objectives:

After completing the independent medical educational activity, learners will be able to:

A. Understand and explain relevant and current clinical trials and updates regarding immunotherapy as maintenance therapy in la/mUC patients.

B. Learn and understand which patients should be followed up with immunotherapy maintenance treatment.

Certificate of attendance:

The certificates will be given to those attendees who will complete pre & post symposium evaluation quiz.

Conflict of interests:

No known conflict of interests

Acknowledgment:

This symposium is supported by an educational grant from Pfizer and Merck.

Role of maintenance immunotherapy in metastatic urothelial carcinoma; which patients are eligible?

23 SEPTEMBER 2021, 5:00 PM CEST

Expert Talk 1: Front-line Management for Advanced Bladder Cancer: Chemo is No Longer Enough

JORGE A. GARCIA

*Oncology University Hospitals Seidman Cancer Center, Cleveland, OH, USA.

Expert Talk 2: Ongoing Clinical Trials in Advanced Urothelial Carcinoma and Future Directions

VADIM KOSHKIN

*Division of Hematology and Oncology, University of California San Francisco

Expert Talk 3: Treatment Options for Second-Line Therapy and Beyond in Urothelial Carcinoma

SHILPA GUPTA

*Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio

Expert Panel Discussion and Questions & Answers

PANELISTS: SHILPA GUPTA, VADIM KOSHKIN AND JORGE A. GARCIA

*Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio,

*Division of Hematology and Oncology, University of California San Francisco and

*Oncology University Hospitals Seidman Cancer Center, Cleveland, OH, USA.

Day 5: 24 September 2021

10:00 (CET)

Advanced ovarian cancer: exploiting exosomes to potentiate the anti-cancer immune response

BRUNA CORRADETTI

Houston Methodist Research Institute, Houston, USA &
School of Medicine at Swansea University, Wales, UK

13:00 (CET)

Imaging of tumor acidosis for monitoring response to novel anticancer therapies

DARIO LONGO

Institute of Biostructures and Bioimaging (IBB), Italian
National Research Council (CNR) Torino, Italy

15:00 (CET)

The Third Dimension in Prostate Cancer

FRANCISCO LA ROSA

University of Colorado, AMC Department of Pathology,
Aurora, CO, US

11:00 (CET)

A phase I study of Affinity-tuned ICAM-1 specific CAR T against advanced thyroid cancer patients

MOONSOO M. JIN

Director, Molecular Imaging Innovations Institute (MI3),
Department of Radiology, Weill Cornell Medicine, New
York, USA

14:00 (CET)

Tensor-Decomposition-Based Unsupervised Feature Extraction Applied to Prostate Cancer Multiomics Data

Y-H. TAGUCHI

Department of Physics, Chuo University, Tokyo, Japan

17:00 (CET)

Solid Tumors: Immuno-Oncology

DISIS, MARY L. (NORA)

Director, Cancer Vaccine Institute, University of Washington
(UW) Director, Institute of Translational Health Sciences UW,
Seattle, WA, USA



Day 6: 25 September 2021

10:00 (CET)

The Role of LIN28B Oncogene in Regulating Migration & Invasion of Neuroblastoma Cells

SANJA AVEIC

Fondazione Istituto di Ricerca Pediatrica Città della Speranza, Padua, Italy RWTH Aachen University Hospital, Dental Materials and Biomaterials Research, Aachen, Germany

11:00 (CET)

The role of General Practitioners in Cancer Control. An underexploited resource in translational oncology

PIER GIORGIO NATALI

Ex. Scientific Director, Regina Elena Institute (IRE), Rome, Italy

14:00 (CET)

Prognostic factors on her2-positive metastatic breast cancer patients treated with trastuzumab emtansine - real-world study (Poster Talk)

MARIA JOÃO SOUSA

Oncology Institute of Coimbra, Coimbra, Portugal

15:00 (CET)

Mutation-Selection Balance and Compensatory Mechanisms in Tumor Evolution

EUGENE V KOONIN

National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD, USA

17:00 (CET)

Translating New Updates on Efficacy of TKIs into Chronic Myelogenous Leukemia (CML) Therapy Practice | satellite symposium

EHAB ATALLAH, GIUSEPPE SAGLIO AND KENDRA SWEET

*Section Head, hematological malignancies, Medical College of Wisconsin, Milwaukee, WI, USA, *Division of Internal Medicine and Haematology, University of Turin, Turin, Italy and *Department of Malignant Hematology H. Lee Moffitt Cancer Center Tampa, FL, USA



EUSTM-2021 on Solid Tumors Therapeutics

<https://eutranslationalmedicine.org/eustm-2021/>

<https://eustm-2021.heysummit.com/>

25 SEPTEMBER 2021, 5:00 PM CEST

Translating New Updates on Efficacy of TKIs into Chronic Myelogenous Leukemia (CML) Therapy Practice

Learning objectives:

After completing the independent medical educational activity, learners will be able to:

A. Improve learners knowledge and understanding about latest evidence-based findings about TKIs efficacy in CML patients with failed prior lines of therapies.

B. Based on the knowledge learned from the activity, learners will be able to develop effective strategies regarding TKIs usage in CML patients with failed prior lines of therapies.

Certificate of attendance:

The certificates will be given to those attendees who will complete pre & post symposium evaluation quiz.

Conflict of interests:

No known conflict of interests

Acknowledgment:

This symposium is supported by an educational grant from Pfizer.

Translating New Updates on Efficacy of TKIs into Chronic Myelogenous Leukemia (CML) Therapy Practice

25 SEPTEMBER 2021, 5:00 PM CEST

Expert Talk 1: Chronic Myelogenous Leukemia (CML)- Monitoring & Mechanisms of resistance

EHAB ATALLAH

*Section Head, hematological malignancies, Medical College of Wisconsin, Milwaukee, WI, USA

Expert Talk 2: Outcomes with Second Line or Later Treatment in CML

KENDRA SWEET

*Department of Malignant Hematology H. Lee Moffitt Cancer Center Tampa, FL, USA

Expert Talk 3: Do we need new TKIs for CML therapy? Yes ! Why ?

GIUSEPPE SAGLIO

*Division of Internal Medicine and Haematology, University of Turin, Turin, Italy

Expert Panel Discussion and Questions & Answers

PANELISTS: EHAB ATALLAH, GIUSEPPE SAGLIO AND KENDRA SWEET

*Section Head, hematological malignancies, Medical College of Wisconsin, Milwaukee, WI, USA, *Division of Internal Medicine and Haematology, University of Turin, Turin, Italy &

*Department of Malignant Hematology H. Lee Moffitt Cancer Center Tampa, FL, USA

Day 7: 26 September 2021

10:00 (CET)

The Role of p63 in the Female Germline Fidelity and Related Cancers

GERRY MELINO

Faculty of Medicine, University of Rome – Tor Vergata, Rome, Italy

11:00 (CET)

The common soil hypothesis for Cancer and Cardiovascular disease: evidence from experimental and epidemiological studies

LICIA IACOVIELLO

IRCCS Neuromed, Pozzilli & University of Insubria Varese, Italy

13:00 (CET)

Apocrine breast carcinoma from biomarkers to therapy

ZORAN GATALICA

Director of Anatomic Pathology, University of Oklahoma Health Sciences Center, Oklahoma, USA.

14:00 (CET)

The Evolution of Precision Medicine- Entering the Era of Multi-omics

JOHN L. MARSHALL

Chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital Director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Washington DC, USA

15:00 (CET)

A lncRNA signature associated with tumour immune heterogeneity predicts distant metastasis in locoregionally advanced nasopharyngeal carcinoma (Poster Talk)

YE-LIN LIANG

Sun Yat-sen University Cancer center, Guangzhou, China

16:00 (CET)

Associating Transcriptomics Data with Inflammatory Markers to Understand Tumour Microenvironment in Hepatocellular Carcinoma (Poster Talk)

BASAK BAHÇIVANCI

College of Medical & Dental Sciences, University of Birmingham, Birmingham, UK





EUSTM-2021
SOLID TUMORS THERAPEUTICS

GLOBAL MULTIDISCIPLINARY CONGRESS ON
**SOLID TUMOR
THERAPEUTICS**

<https://eutranslationalmedicine.org/eustm-2021/>

<https://eustm-2021.heysummit.com/>